168 completed, 55 unknown, 16 recruiting, 13 terminated. 277 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 277 | Completed 168, Unknown 55, Recruiting 16, Terminated 13, Withdrawn 9, Not yet recruiting 8, Active not recruiting 5, Suspended 2, Enrolling by invitation 1 |
Follow Type 2 Diabetes: new trials by email Literature Review of Type 2 Diabetes trials Research Report on Type 2 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes Insulin icodec - Type 2 Diabetes | Phase 4 | Not yet recruiting | Xi'an International Medical Center Hospital | 462 | 2027-01-01 | 2026-08-05 |
| Efficacy of Topical Lidocaine Gel vs. Oral Duloxetine for Painful Diabetic Peripheral Neuropathy Topical Lidocaine 2% Gel, Duloxetine (60 MG) - Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies | Phase 4 | Not yet recruiting | Wah Medical college , POF hospital | 80 | 2026-12-01 | 2026-09-02 |
| PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon) Eroxon®, tadalafil - Type 2 Diabetes, Type 2 Diabetes (T2DM) | Phase 4 | Suspended | University of Miami | 30 | 2026-10-01 | 2026-09-28 |
| Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes semaglutide, Moderate-Intensity Resistance Exercise, Balance and Tone (BAT) Exercise - Type 2 Diabetes, Cognitive Decline in Older Adults | Phase 4 | Not yet recruiting | Western University, Canada | 164 | 2026-09-01 | 2026-08-20 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes GLP-1 Receptor Agonists - Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) | Phase 4 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 60 | 2026-04-01 | 2026-04-30 |
| Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes CSII, Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin Degludec and Insulin Aspart Injection - Type 2 Diabetes | Phase 4 | Not yet recruiting | Yanbing Li | 324 | 2026-03-15 | 2026-02-06 |
| Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) Insulin, DEXCOM Continuous Glucose Monitor - Pregnancy, High Risk, Type 1 Diabetes | Phase 4 | Recruiting | Ohio State University | 44 | 2026-02-25 | 2026-11-09 |
| A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) Dapagliflozin (10Mg Tab) along with standard medical therapy, Empagliflozin (25 Mg Tab) along with standard medical therapy - Type 2 Diabetes | Phase 4 | Not yet recruiting | Bhavya Bhavya, MD | 112 | 2025-12-24 | 2025-12-31 |
| Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs) - Type 2 Diabetes | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 1316 | 2025-12-13 | 2026-07-07 |
| The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms Semaglutide 1.0 mg, Semaglutide 0.5 mg - Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes | Phase 4 | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 60 | 2025-10-01 | 2025-07-18 |
| The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity Empagliflozin (oral), Dapagliflozin (DAPA), Metfomin - Type 2 Diabetes, Obese Diabetics | Phase 4 | Completed | Erbil Polytechnic University | 260 | 2025-07-15 | 2026-03-17 |
| A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin - Type 2 Diabetes | Phase 4 | Recruiting | Boryung Pharmaceutical Co., Ltd | 204 | 2025-06-11 | 2025-09-15 |
| Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes Semaglutide Injectable Product, Placebo - Spinal Cord Injuries, Type 2 Diabetes | Phase 4 | Recruiting | Marzieh Salehi | 50 | 2025-04-11 | 2026-10-05 |
| Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes SGLT2 inhibitor - Type 2 Diabetes | Phase 4 | Completed | Assiut University | 482 | 2025-04-01 | 2026-09-10 |
| Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease Glucophage (Metformin Hydrochloride Tablets), New sustained-release metformin tablets (Ⅲ) - Atherosclerotic Heart Disease, Type 2 Diabetes | Phase 4 | Recruiting | China National Center for Cardiovascular Diseases | 356 | 2025-03-04 | 2025-04-30 |
| Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide Insulin resistance testing, OGTT, Fat biopsy - Diabetes Mellitus, Type 2, Diabetes | Phase 4 | Recruiting | Stanford University | 104 | 2025-01-13 | 2026-04-20 |
| Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM D-Chiro-Inositol Combined with Metformin, Placebo in combination with metformin - Type 2 Diabetes, Overweight and Obese Adults | Phase 4 | Active not recruiting | Campus Bio-Medico University | 16 | 2025-01-10 | 2025-03-11 |
| A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus iGlarLixi (insulin glargine/lixisenatide) - Type 2 Diabetes | Phase 4 | Completed | Sanofi | 105 | 2025-01-06 | 2026-07-10 |
| Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos] - Type 2 Diabetes, Fatty Liver | Phase 4 | Recruiting | Seoul National University Bundang Hospital | 120 | 2025-01-01 | 2025-05-25 |
Showing 20 of 277. Sign in to see all of them.
Diabetes Mellitus, Type 2 (277) · Diabetes Mellitus (45) · Insulin Resistance (26) · Obesity (21) · Hypertension (11) · Non-alcoholic Fatty Liver Disease (9) · Overweight (9) · Coronary Artery Disease (7) · Fatty Liver (6) · Hyperglycemia (6) · Inflammation (6) · Atherosclerosis (5) · Cardiovascular Diseases (5) · Diabetic Nephropathies (5) · Dyslipidemias (5)
Endocrine System Diseases (277) · Nutritional and Metabolic Diseases (277) · Metabolic Diseases (275) · Glucose Metabolism Disorders (274) · Diabetes Mellitus (232) · Pathological Conditions, Signs and Symptoms (48) · Signs and Symptoms (35) · Cardiovascular Diseases (29) · Vascular Diseases (29) · Hyperinsulinism (28) · Nutrition Disorders (25) · Overnutrition (25) · Body Weight (23) · Overweight (16) · Female Urogenital Diseases (15)
Metformin (41) · Insulin Glargine (32) · Sitagliptin Phosphate (25) · Pioglitazone (23) · Liraglutide (22) · dapagliflozin (20) · semaglutide (15) · Exenatide (13) · Insulin (12) · Vildagliptin (12) · glimepiride (12) · empagliflozin (11) · Insulin Aspart (10) · saxagliptin (9) · Linagliptin (8)
Emory University (10) · Eli Lilly and Company (9) · Shanghai Jiao Tong University School of Medicine (8) · Seoul National University Bundang Hospital (7) · Lund University (5) · Novartis Pharmaceuticals (5) · The University of Texas Health Science Center at San Antonio (5) · Amsterdam UMC, location VUmc (4) · Shanghai Zhongshan Hospital (4) · University of Campania Luigi Vanvitelli (4) · University of Miami (4) · Beijing Chao Yang Hospital (3) · Centre Hospitalier Universitaire Dijon (3) · Mayo Clinic (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)
United States (88) · China (35) · South Korea (18) · Italy (14) · Germany (12) · United Kingdom (12) · Canada (11) · Denmark (11) · France (7) · Japan (7) · Sweden (7) · Mexico (5) · Netherlands (5) · Taiwan (5) · Egypt (4)
Guillermo Umpierrez, MD (6) · Guang Ning, MD. PHD (4) · Adrian Vella, MD (3) · Edward Jude, MD, MRCP (2) · Guang Wang, MD (2) · Guillermo E Umpierrez, MD (2) · Katherine Esposito, MD, PhD (2) · Kun-Ho Yoon, M.D., Ph.D. (2) · Ralph A DeFronzo, MD (2) · Soo Lim, MD, PhD (2) · William Cefalu, MD (2) · Xiaoying Li, MD (2)
PMID 12716821, PMID 16014401, PMID 16105050, PMID 16842478, PMID 17327353, PMID 17473060, PMID 17804683, PMID 19016075, PMID 19017758, PMID 19055828, PMID 19104769, PMID 19259827, PMID 19336639, PMID 19366972, PMID 19741187, PMID 19755697, PMID 19809363, PMID 19940224, PMID 19943971, PMID 20022616, PMID 20084363, PMID 20460434, PMID 20739421, PMID 20863646, PMID 20877288, PMID 20937657, PMID 21104573, PMID 21105792, PMID 21228246, PMID 21340022, PMID 21529978, PMID 21652249, PMID 21708874, PMID 21733334, PMID 21775756, PMID 21932999, PMID 21957032, PMID 22030226, PMID 22056385, PMID 22104550, PMID 22474419, PMID 22492381, PMID 22699288, PMID 22773702, PMID 23011489, PMID 23025537, PMID 23147277, PMID 23230096, PMID 23250357, PMID 23273975
2015 (3), 2008 (2), 2019 (2), 2009 (1), 2014 (1), 2016 (1), 2023 (1), K12HD057022 (1), K23DK075931 (1), K23DK131345 (1), M01RR000827 (1), P20MD002295 (1), P30DK063491 (1), P60DK020593 (1), R01DK069861 (1)